Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Villejuif – page 151

3 340 clinical trials in Villejuif, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villejuif at a glance
3 340
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 340 trials in Villejuif

Open in trial search

Breast cancer

Not recruiting

Study of Camizestrant plus Ribociclib as First‑Line Treatment for Patients with ER‑Positive, HER2‑Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Hereditary ataxia

Not recruiting

Safety and tolerability of intrathecal S233107 in participants with spinocerebellar ataxia type 3: a Phase 1b/2a first‑in‑human randomized study

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:S233107
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Obesity

Not recruiting

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Cardiac amyloidosis

Not recruiting

Efficacy and safety of eplontersen sodium plus ALXN2220 in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:AstraZeneca AB

Multiple sclerosis

Not recruiting

Safety and Feasibility of Home Use On-Body Injection System for Subcutaneous Ocrelizumab in Adults with Multiple Sclerosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Ovarian cancer

Not recruiting

Open‑Label Extension Study of Avutometinib Alone or with Defactinib in Patients with Recurrent Low‑Grade Serous Ovarian Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avutometinib
  • Sponsor:Verastem Inc.

Hepatocellular carcinoma

Not recruiting

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Dermatomyositis+3

Not recruiting

Phase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Colorectal cancer

Not recruiting

Study of denikitug alone or in drug combination in adults with advanced microsatellite stable colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gilead Sciences Inc.

Non-small cell lung cancer

Not recruiting

Continuation study of JDQ443 in patients with KRAS G12C‑mutated non‑small cell lung cancer receiving JDQ443 as monotherapy or drug combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Novartis Pharma AG

Breast cancer

Not recruiting

Study of alpelisib with trastuzumab and pertuzumab as maintenance therapy in adult patients with HER2‑positive advanced breast cancer and PIK3CA mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Celcuity Inc.

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

  • NBTXR3 with radiotherapy
  • EGFR-ADC therapy combinations
  • HPV-positive oropharyngeal cancer
02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

  • Anti-CEACAM5 ADC therapy
  • Sotorasib combinations
  • Novel gastrointestinal cancer treatments
03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

  • Elranatamab-lenalidomide therapy
  • Belantamab mafodotin combinations
  • T-cell lymphoma treatments
04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

  • Novel antibody-drug conjugates
  • Microbiome-based approaches
  • Targeted therapy combinations
05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

  • PARG inhibitor studies
  • Targeted molecular therapies
  • Immunotherapy combinations
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.